Four Seasons Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
as on 22-12-2024
- Paid Up Capital ₹ 2.25 M
as on 22-12-2024
- Company Age 12 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.07 M
as on 22-12-2024
About Four Seasons Pharmaceuticals
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 2.25 M.
The company currently has active open charges totaling ₹1.07 M.
Tribhuwan Das, Vaibhav Rastogi, Meenu Parmar, and One other member serve as directors at the Company.
- CIN/LLPIN
U33111UP2012PTC049721
- Company No.
049721
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Apr 2012
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Lucknow, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Four Seasons Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Tribhuwan Das  | Director | 04-Apr-2012 | Current |
| Vaibhav Rastogi | Director | 12-Apr-2012 | Current |
| Meenu Parmar | Director | 04-Apr-2012 | Current |
| Jaspal Parmar | Director | 04-Nov-2019 | Current |
Financial Performance of Four Seasons Pharmaceuticals.
Four Seasons Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Four Seasons Pharmaceuticals?
In 2017, Four Seasons Pharmaceuticals had a promoter holding of 30.00% and a public holding of 70.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- M.M. Remedies Private LimitedActive 26 years 7 months
Tribhuwan Das and Vaibhav Rastogi are mutual person
- Kant Drugs Private LimitedActive 23 years 10 months
Tribhuwan Das and Vaibhav Rastogi are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 02 Jul 2021 | ₹1.07 M | Open |
How Many Employees Work at Four Seasons Pharmaceuticals?
Four Seasons Pharmaceuticals has a workforce of 18 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Four Seasons Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Four Seasons Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
